Nouri, Nima http://orcid.org/0000-0001-8348-5717
Cao, Raquel Giacomelli
Bunsow, Eleonora
Nehar-Belaid, Djamel http://orcid.org/0000-0001-6002-5021
Marches, Radu
Xu, Zhaohui http://orcid.org/0000-0003-0645-1737
Smith, Bennett
Heinonen, Santtu http://orcid.org/0000-0002-1666-1933
Mertz, Sara
Leber, Amy
Smits, Gaby
van der Klis, Fiona
Mejías, Asunción http://orcid.org/0000-0002-5983-8006
Banchereau, Jacques
Pascual, Virginia http://orcid.org/0000-0002-8806-8426
Ramilo, Octavio http://orcid.org/0000-0002-0565-5239
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI131386, AI168632)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 6 March 2023
Accepted: 17 November 2023
First Online: 2 December 2023
Competing interests
: While this study was performed, J.B. served on the Board of Directors (BOD) for Neovacs, is a BOD member and stockholder for Ascend Biopharmaceuticals, Scientific Advisory Board (SAB) member for Cue Biopharma, and stockholder for Sanofi. J.B. is currently an employee of Immunai and holds shares from Immunai, Merck and Novartis. N.N. currently holds the position of principal scientist at Sanofi. A.M. has received research grants from Janssen and Merck, fees for participation in advisory boards from Janssen, Merck, Sanofi-Pasteur, and fees for lectures from Sanofi-Pasteur and Astra-Zeneca. O.R. has received research grants from the Bill & Melinda Gates Foundation, Merck and Janssen; and fees for participation in advisory boards from Merck, Sanofi-Pasteur, Lilly, Pfizer and Adagio; and fees for lectures from Pfizer, Astra-Zeneca, and Sanofi-Pasteur. None of these fees were related to the research described in this manuscript. The remaining authors declare no competing interests.